Chemically attenuated blood-stage Plasmodium yoelii parasites induce long-lived and strain-transcending protection by Raja, Amber I et al.
Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites
Induce Long-Lived and Strain-Transcending Protection
Amber I. Raja,a Yeping Cai,b Jennifer M. Reiman,a Penny Groves,c Sumana Chakravarty,d Virginia McPhun,a Denise L. Doolan,c
Ian Cockburn,b Stephen L. Hoffman,d Danielle I. Stanisic,a Michael F. Gooda
Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australiaa; John Curtin School of Medical Research, Australian National University, Acton, Australian
Capital Territory, Australiab; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australiac; Sanaria, Inc., Rockville, Maryland, USAd
The development of a vaccine is essential for the elimination of malaria. However, despite many years of effort, a successful vac-
cine has not been achieved. Most subunit vaccine candidates tested in clinical trials have provided limited efficacy, and thus at-
tenuated whole-parasite vaccines are now receiving close scrutiny. Here, we test chemically attenuated Plasmodium yoelii 17X
and demonstrate significant protection following homologous and heterologous blood-stage challenge. Protection against
blood-stage infection persisted for at least 9 months. Activation of both CD4 and CD8 T cells was shown after vaccination;
however, in vivo studies demonstrated a pivotal role for both CD4 T cells and B cells since the absence of either cell type led to
loss of vaccine-induced protection. In spite of significant activation of circulating CD8 T cells, liver-stage immunity was not
evident. Neither did vaccine-induced CD8 T cells contribute to blood-stage protection; rather, these cells contributed to patho-
genesis, since all vaccinated mice depleted of both CD4 and CD8 T cells survived a challenge infection. This study provides
critical insight into whole-parasite vaccine-induced immunity and strong support for testing whole-parasite vaccines in humans.
Malaria is a major global health burden, with nearly half of thehuman population at risk of becoming infected with Plas-
modium parasites (1). In 2015 there were an estimated 214 million
clinical cases and a malaria-associated death toll of approximately
438,000 (1). Although malaria control measures, such as insecti-
cide-treated nets, indoor residual spraying, and antimalaria drug
treatment, have contributed to a reduction in morbidity and mor-
tality (1), additional strategies, such as a vaccine, will be required
for the continued reduction and eventual eradication of human
malaria.
The development of malaria vaccines has largely focused on a
limited number of recombinant subunit vaccine candidates, im-
mune responses to which have shown an association with protec-
tion in immunoepidemiological studies (2–4). Many of these im-
mune targets, such as merozoite surface proteins 1 and 2 that are
involved in the invasion of red blood cells (RBCs), are encoded by
multiple alleles. The genetic diversity of Plasmodium, especially
allelic polymorphism, has been a major stumbling block for
subunit vaccine candidates, and this has undoubtedly impacted
their ability to provide sustained protection in endemic set-
tings (5–7). The most advanced vaccine candidate, RTS,S, targets
the preerythrocytic stage of the parasite’s life cycle. This subunit
vaccine candidate is based on the Plasmodium falciparum circum-
sporozoite surface protein. Data from clinical trials suggest that
RTS,S is only able to induce temporary immunity and is unable to
provide protection to residents of regions of endemicity over a
sustained period of time (8–12). Therefore, efforts in malaria vac-
cine development need to continue in order to develop more ef-
ficacious vaccines.
An alternative approach to malaria vaccine development is to
use the whole parasite. This is now being vigorously pursued for
the sporozoite stage of the life cycle with significant initial success
(13, 14). A vaccine approach using whole blood-stage parasites is
advantageous as it includes a broad array of antigens, including
those that are conserved between different parasite strains and
species and, if successful, will reduce the morbidity and mortality
of malaria, even if does not completely prevent infection. The
inclusion of conserved antigens may result in the induction of a
protective strain- and species-transcending immune response and
therefore result in improved efficacy compared with subunit vac-
cine candidates. Protection induced by whole blood-stage malaria
parasites has been studied using infection and drug-cure systems
(15–17); these data provide a strong rationale for the development
of a whole-parasite vaccine. Attenuation of the malaria parasite,
such as by chemical treatment using DNA-binding drugs, has pro-
vided the means for investigating this approach (18–20). In a ro-
dent model, vaccination with chemically attenuated synchronous
Plasmodium chabaudi ring-stage parasites was shown to protect
mice against parasite challenge (20). Although these results are
encouraging, they do not indicate that attenuated whole blood-
stage parasites will provide a general strategy for vaccine develop-
ment, in particular for parasites where cellular tropism and se-
questration differ and where different mechanisms of immunity
are known to be relevant. Plasmodium yoelii, like the human par-
asite Plasmodium vivax, has a tropism for reticulocytes. Mature
forms of both parasites are also found in the peripheral blood,
unlike P. falciparum and P. chabaudi, where only immature ring
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forms are found in peripheral blood. In addition, the mechanism
of immunity for P. yoelii differs from that for P. chabaudi. Immu-
nity to P. chabaudi after infection and drug-cure is thought to be
mediated predominantly by T cells (21), although antibodies are
known to play a role later in protection (22). Conversely, antibod-
ies are thought to play a primary role in immunity to P. yoelii (23).
Furthermore, in some parasite species, the activation of cellular
immune responses was shown to be associated with the induction
of pathology (24). These various observations indicate the need
for further preclinical investigations of the attenuated blood-stage
malaria vaccine strategy.
Here, we have used the DNA-binding drug centanamycin to
attenuate blood-stage P. yoelii 17X parasites and investigated the
protective efficacy of this vaccine. Since P. yoelii exists asynchro-
nously during the blood-stage of its life cycle (25), we were able to
investigate a blood-stage vaccine expressing antigens from all
stages of asexual blood-stage parasite development. We found that
the attenuated vaccine induced profound stage-specific immunity
and long-lived immunological memory, with protection depen-
dent on both CD4 T cells and B cells. Cell depletion studies
revealed that CD8 T cells could play a significant role in patho-
genesis.
MATERIALS AND METHODS
Ethics statement. Animal work was approved by the Griffith University
Animal Ethics Committee under approvals BDD/07/10 and GLY/05/12.
Sporozoite challenge by mosquito bite and intravenous injection of
freshly dissected sporozoites was approved by the Australian National
University Animal Experimentation Ethics Committee under approval
A2013/12. All animal care and use protocols adhered to the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes.
Mice. Six- to eight-week-old female BALB/c, C57BL/6, andMT mice
were used. BALB/c and C57BL/6 mice were obtained from Animal Re-
source Centre, Perth, Australia.MT mice were originally obtained from
the Jackson Laboratory (Bar Harbor, ME) and were backcrossed on the
C57BL/6 background for10 generations. Mice were housed under PC2
and QAP (where applicable) regulations.
Malaria parasites. The nonlethal phenotype of P. yoelii 17XNL was
not always stable between experiments; therefore, rather than refer to the
parasite as P. yoelii 17XNL or 17XL, here, the strain is referred to as P.
yoelii 17X. Blood-stageP. yoelii 17X andP. yoeliiYM strains were obtained
from Richard Carter (Edinburgh, United Kingdom) and maintained by
serial passage in inbred and outbred mice. P. yoelii 17X sporozoites that
were used in the mosquito bite challenge and freshly dissected sporozoite
challenge studies were obtained from Fidel Zavala (Johns Hopkins Uni-
versity, Baltimore, MD) under Australian quarantine guidelines. Cryo-
preserved P. yoelii 17X sporozoites (26, 27) were obtained from Stephen
Hoffman (Sanaria, Inc., Rockville, MD) under Australian quarantine
guidelines.
Attenuation and vaccination of mice. For parasite attenuation, P.
yoelii 17X-infected blood was collected into EDTA or lithium-heparin
blood collection tubes (BD Biosciences). Blood was diluted to 10% (vol/
vol) in serum-free RPMI 1640 (Gibco). The attenuating drug, centana-
mycin, was dissolved in dimethyl sulfoxide (Sigma-Aldrich), PET (6 parts
of polyethylene glycol 400 [Sigma-Aldrich], 3 parts of 100% ethanol [Sig-
ma-Aldrich], and 1 part of Tween 80 [Merck]) and 5% glucose (Sigma-
Aldrich) to produce a 2 mM stock. A final concentration of 2 M cen-
tanamycin was used to attenuate parasites. Parasites were incubated with
the attenuating drug for 40 min (with agitation every 10 min) at 37°C in
CO2. Treated parasitized RBCs (pRBCs) were washed twice with RPMI
1640 and once with phosphate-buffered saline (PBS) at 277  g for 10
min. The cells were resuspended in 0.9% saline (Pfizer) or PBS. Viable
cells were counted based on the exclusion of dead cells by trypan blue
(0.1% [wt/vol] in PBS). The immunizing dose of 106 pRBCs was calcu-
lated, and mice were injected intravenously. Control groups received 106
normal RBCs (nRBCs) that were treated with centanamycin as described
above.
Challenge of mice with blood-stage parasites or sporozoites and
monitoring of disease. For blood-stage parasite challenge, control and/or
vaccinated mice were challenged by intravenous injection with 105 P.
yoelii 17X or P. yoelii YM pRBCs in 0.9% saline (Pfizer) or PBS.
For sporozoite challenge by mosquito bite, mice were anesthetized
using ketamine (100 mg/kg)-xylazine (10 mg/kg) and laid over a cage
containing 50 P. yoelii 17X-infected mosquitoes. Each mouse received
10 mosquito bites over 30 min. Livers from mice were removed 40 to 42
h after sporozoite challenge.
For challenge with freshly dissected sporozoites by intravenous injec-
tion, P. yoelii 17X sporozoites were dissected from the salivary glands of
infected mosquitoes at between 14 and 21 days postinfection. The number
of sporozoites was determined using a counting chamber, and the sporo-
zoites were diluted in PBS containing 1% heat-inactivated naive mouse
serum. Mice were injected intravenously with 2,000 sporozoites in a vol-
ume of 200l. Livers from mice were removed 40 to 42 h after sporozoite
injection.
For challenge by intravenous injection of cryopreserved sporozoites,
P. yoelii 17X sporozoites (Sanaria, Inc.) were thawed in a 30°C water bath
for 30 s. The vial was centrifuged briefly, and sporozoites were diluted in
PBS containing 5% naive mouse serum. Mice were injected intravenously
with 4,000 sporozoites in a volume of 200l. Infection in mice was either
followed through to blood-stage infection or the livers were removed
from mice 40 to 42 h after sporozoite injection.
After challenge, the mice were monitored every other day by examin-
ing stained thin blood films and every 4 days by measuring hemoglobin
levels (HemoCue 201 Analyser; Hemocue). To reduce observer bias, all
experiments, except for the T cell depletion study, were monitored with
the observer blind to the identification of the experimental groups. Clin-
ical scoring criteria (described in Table S1 in the supplemental material)
were used to monitor disease every 2 days. Mice that showed signs of
severe disease were euthanized using CO2 gas or by cervical dislocation.
Detection of IgG against crude parasite antigen by enzyme-linked
immunosorbent assay. Blood was collected from mice at specific time
points pre- and postchallenge and diluted 1 in 20 in PBS. The samples
were centrifuged at 8,928 g for 5 min, and the supernatant was removed
and stored at 80°C. Ninety-six-well MaxiSorp Nunc immunoplates
(Nunc) were coated with 10 g/ml of crude parasite antigen in coating
buffer for 2 h at room temperature. Plates were blocked with 5% skim
milk in PBS overnight at 4°C. Serum samples were used at a 1 in 20
dilution or titrated using 3-fold dilutions from 1 in 50 to 1 in 109,350.
Samples were dispensed at a volume of 50 l per well and incubated for 2
h at room temperature. For the assessment of memory B cell responses, a
dilution of 1 in 1,350 of the titrated sera was chosen as a representation of
the data. After five washes with PBS– 0.05% Tween 20 (Merck), the plates
were incubated with goat anti-mouse IgG/horseradish peroxidase-conju-
gated antibody (1:3,000 in blocking buffer) (Bio-Rad) for 2 h. Plates were
washed a further five times and then incubated with tetramethylbenzidine
substrate (BD Biosciences) for 15 min. The reaction was stopped using 1
M sulfuric acid, and the plates were read using a Victor 3 plate reader
(Perkin-Elmer) at 450 nM.
Analysis of vaccine-induced CD4 T follicular helper cells. Spleens
were removed from mice, broken down manually, and then lysed with
Geys lysis buffer. The splenocytes were washed with MACS buffer (PBS
supplemented with bovine serum albumin and EDTA) at 277  g for 5
min and dispensed at 3 106 cells per well in MACS buffer into V-bottom
96-well plates (Sarstedt). The cells were incubated in 100l of Fc receptor
block (from cell line 2.4G2; ATCC) for 10 min on ice and centrifuged at
177  g for 3 min. The supernatants were removed, and the cells were
resuspended and incubated with CD4-fluorescein isothiocyanate (CD4-
FITC) (clone GK1.5; BD Pharmingen), CD3-V450 (clone 17A2; BD Phar-
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mingen), and CXCR5-biotin (clone 2G8; BD Pharmingen) on ice for 20
min. The cells were washed twice in MACS buffer. Streptavidin-allophy-
cocyanin (streptavidin-APC) (BD Pharmingen) was added to each well,
and the cells were incubated for 15 min on ice and washed at 177 g for
3 min. Fix/Perm buffer (eBioscience) was added, and the cells were incu-
bated for 30 min on ice. The cells were washed twice with Perm/Wash
buffer (eBioscience) at 177 g for 3 min, the supernatants were removed,
and the cells were resuspended. Bcl6-PE (clone K112-91; BD Pharmin-
gen) was added to each well, and the cells were incubated on ice for an
hour. The cells were washed and resuspended in Perm/Wash buffer for
analysis on an LSR Fortessa flow cytometer (BD Biosciences). Data anal-
ysis was performed using FACSDiva software version 6 (BD Biosciences)
and FlowJo software version 7.6.5 (FlowJo, LLC). The gating strategy in
Fig. S1 in the supplemental material was used to identify T follicular
helper (Tfh) cells.
Assessment of T cell activation. Fifty microliters of blood was col-
lected from vaccinated and control mice on day 7 after each injection.
Blood was collected into 1 ml of 5 mM EDTA (Gibco) in PBS. Samples
were centrifuged at 400  g for 5 min, and the supernatants were re-
moved. One milliliter of ammonium-chloride-potassium (ACK) lysis
buffer was added per sample, followed by incubation for 5 min at room
temperature. The samples were centrifuged at 400  g for 5 min and
supernatants were removed. Samples were resuspended in 100 l of
MACs buffer and transferred to a V-bottom 96-well plate (Sarstedt). The
samples were centrifuged and resuspended in 60 l of Fc receptor block
(from cell line 2.4G2; American Type Culture Collection [ATCC]) and
incubated for 10 min on ice. The samples were centrifuged, and 50l of an
antibody mastermix containing CD4 (RM4-5, V500; BD Horizon), CD8
(53.6.7, peridinin chlorophyll protein [PerCP]-Cy5.5; BD Pharmingen),
CD11a (2D7, FITC, BD Pharmingen), and CD49d (R1-2, phycoerythrin
[PE]; BD Pharmingen) in MACS buffer was added per well. The cells were
incubated on ice for 20 min and washed three times in MACS buffer by
centrifugation at 400  g for 5 min. The cells were then resuspended in
300 l of MACS buffer. Samples were analyzed using the LSR Fortessa
flow cytometer (BD Biosciences), FACSDiva software version 6 (BD Bio-
sciences), and FlowJo software version 7.6.5 (FlowJo, LLC). The gating
strategy in Fig. S2 in the supplemental material was used to identify acti-
vated T cells.
Depletion of CD4 and CD8 T cells. Following a regimen of three
vaccine doses, mice were depleted of CD4 T cells, CD8 T cells, or both
CD4 and CD8 T cells. Depletions were undertaken using intraperito-
neal injections of anti-CD4 antibodies from the supernatant of the clone
GK1.5 (Bio-x-cell) at 0.25 mg per mouse (depletion of CD4 T cells),
anti-CD8 antibodies from supernatant of the clone 53.5.8 (Bio-x-cell) at
0.5 mg per mouse (depletion of CD8 T cells), or a combination of 0.25
mg per mouse of anti-CD4 and 0.5 mg per mouse of anti-CD8 antibodies
(depletion of CD4 and CD8 T cells) from day 3 to day 0 relative to
challenge on day 0. The gating strategy in Fig. S3 in the supplemental
material was used to identify CD4 and CD8 T cells. Depletions were main-
tained by continued injections of the relevant antibodies on day 7, 15, and
22 relative to challenge on day 0. A control group of vaccinated mice
received intraperitoneal injections of 0.5 mg per mouse rat Ig antibodies
(Sigma-Aldrich) at each time point.
Splenocyte proliferation and cytokine assays. Spleens were removed
from mice, broken down manually, and then lysed with Geys lysis buffer.
Splenocytes were washed with complete RPMI medium (RPMI supple-
mented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine
[100], 1% penicillin-streptomycin, and 0.1% 2-mercaptoethanol) at 277
g for 5 min and dispensed at 4 105 cells per well in complete medium into
U-bottom 96-well plates (BD Falcon). Cultures were grown for 72 h at 37°C
and 5% CO2 in the presence of complete medium (negative control), 5 10
6
normal RBCs from a naive mouse (nRBCs)/ml (negative control), 10 g of
concanavalin A (Sigma-Aldrich)/ml (a T cell-specific mitogen, positive con-
trol), or 5 106 pRBCs/ml.
To measure the cytokines secreted by cultured splenocytes, culture
supernatants were removed after 54 h, aliquoted, and stored at80°C just
prior to the addition of [3H]thymidine. Interleukin-2 (IL-2), IL-4, IL-6,
IL-10, IL-17, gamma interferon (IFN-	), and tumor necrosis factor
(TNF) were measured in culture supernatants using a Th1/Th2/Th17
CBA kit (BD Biosciences) according to the manufacturer’s instructions
with the following modifications. One hundred eighty microliters of assay
diluent was added to a 20-l aliquot of reconstituted standard. Serial
dilutions of the standard were made. Then, 20l of a master mix contain-
ing 2l of each vortexed capture bead per sample and an equal volume of
PE detection reagent was added per well to a V-bottom 96-well plate
(Sarstedt). Next, 10 l of the standards and samples was added to the
appropriate wells and incubated for 2 h at room temperature. The wells
were washed with 150 l of wash buffer and centrifuged at 177 g for
3 min. The supernatants were removed, and the samples were resus-
pended in 200 l of wash buffer. The samples were analyzed using a LSR
Fortessa flow cytometer (BD Biosciences), FACSDiva software version 6
(BD Biosciences), and FCAP Array software version 1.0.1 (BD Biosci-
ences).
The uptake of [3H]thymidine (radioisotope-labeled nucleoside; Per-
kin-Elmer) was used to assess splenocyte proliferation. Cultured spleen
cells were pulsed with 1 Ci of [3H]thymidine per well for the last 18 h of
the 72-h culture period. Plates were stored at80°C prior to thawing and
harvesting of cells onto glass fiber filter mats (Perkin-Elmer). Radioiso-
tope incorporation was estimated by 
-emission spectroscopy using a
MicroBeta2 
 counter (Perkin-Elmer).
Quantification of liver-stage parasites by RT-qPCR. Method 1. For
method 1, the livers were removed from mice 40 to 42 h after mosquito
bite or intravenous injection with freshly dissected sporozoites. RNA was
extracted from the liver as previously described (28). cDNA synthesis was
carried out using an iScript cDNA synthesis kit (Bio-Rad) in accordance
with the manufacturer’s instructions. Reverse transcription-quantitative
PCR (RT-qPCR) to determine the level of P. yoelii 18S rRNA was per-
formed using the forward primer NYU-Py3 (5=-GGGGATTGGTTTTGA
CGTTTTTGCG-3=) and the reverse primer NYU-Py5 (5=-AAGCATTAA
ATAAAGCGAATACATCCTTAT-3=) (29). Briefly, the Py18S PCR was
conducted using Power SYBR Green PCR master mix (Applied Biosys-
tems), 0.5M concentrations (each) of forward and reverse primer, and 1
l of template (negative controls, unknown samples, positive control, or
standard curve). The PCR was performed using a thermal profile of 50°C
for 2 min, followed by 95°C for 10 min, followed by 40 cycles of 95°C for
15 s and 60°C for 1 min, and then terminated by 95°C for 15 s, 60°C for 1
min, 95°C for 15 s, and 60°C for 15 s on an Applied Biosystems 7500
real-time PCR system. A PCR for the housekeeping gene GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase) using the forward primer (5=-G
TTGTCTCCTGCGACTTCA) and reverse primer (5=-GGTGGTCCAGG
GTTTCTTA) was run to control for sample to sample variation; cycling
conditions and other parameters were the same as for the P. yoelii 18s
rRNA reaction.
Method 2. For method 2, the livers were removed from mice 40 to 42
h after intravenous injection of cryopreserved sporozoites. RNA was ex-
tracted from the livers as previously described (30). The concentration
and purity of RNA were measured using a Nanodrop2000c spectropho-
tometer (Thermo Scientific). cDNA synthesis was carried out using a Su-
perScript VILO cDNA synthesis kit (Invitrogen) in accordance with the
manufacturer’s instructions. RT-qPCR to determine the level of P. yoelii
18S RNA was performed using the forward primer Py685F (5=-CTTGGC
TCCGCCTCGATAT), the reverse primer Py782R (5=-TCAAAGTAACG
AGAGCCCAATG), and a probe (6-carboxyfluorescein [FAM]-CTGGCC
CTTTGAGAGCCCACTGATT-BHQ-1) (31). Briefly, the Py18S PCR was
conducted using TaqMan Fast Advanced Master mix (Applied Biosys-
tems), 1 M concentrations (each) of forward and reverse primers, 0.25
M probe (Sigma-Aldrich), and 2 l of template (negative controls, un-
known samples, positive control, or standard curve). The PCR was run
using a thermal profile of 50°C for 2 min and 95°C for 2 min, followed by
50 cycles of 95°C for 5 s and 60°C for 30 s on the FAM channel using a
Raja et al.
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Bio-Rad (CFX96) real-time PCR machine. A PCR for the GAPDH
housekeeping gene was run to control for sample-to-sample variation.
Briefly, the PCR was conducted using a GAPDH kit (Mm03302249_g1,
Applied Biosystems), Platinum Taq (Life Technologies), 200M deoxy-
nucleoside triphosphates (Promega), and 2 l of template (negative con-
trols, unknown samples, positive control, or standard curve). The PCR
was run using a thermal profile of 95°C for 2 min, followed by 45 cycles of
95°C for 5 s and 60°C for 30 s on the FAM channel using the Bio-Rad
(CFX96) real-time PCR machine.
Statistical analysis. All statistical analyses were conducted using
GraphPad Prism software version 6. An unpaired, two-tailed t test was
used when comparing two experimental groups. For experiments com-
paring more than two groups, a one-way analysis of variance (ANOVA)
was used, followed by Tukey’s multiple-comparison tests.
RESULTS
Vaccine-induced immune protection against homologous and
heterologous parasites. A regimen of three vaccine doses of 106
chemically attenuatedP. yoelii 17X-parasitized RBCs (pRBCs) was
used to vaccinate BALB/c mice. The control group received chem-
ically treated normal RBCs (nRBCs) at each time point. We sought
to determine whether vaccination induced activation of CD4
and CD8 T cells using CD49d and CD11a as markers of recent
activation (32, 33). Overall, circulating CD4 T cells showed lim-
ited activation in vaccinated mice compared to control mice (Fig.
1A). Significant activation of CD8 T cells was identified in the
blood of mice vaccinated with chemically attenuated blood-stage
P. yoelii 17X parasites compared to control mice (P 0.0001).
Prior to challenge, there was significantly higher P. yoelii 17X-
specific IgG in the sera of vaccinated mice than in the sera of
control mice (P 0.0001) (Fig. 1B). We observed that these anti-
bodies cross-reacted with the heterologous strain, P. yoelii YM
(Fig. 1C).
Immediately prior to challenge, a subset of mice from each
group was sacrificed to assess splenocyte proliferation in response
to homologous parasites. Parasite-specific cellular proliferation
was significantly higher for spleen cells from vaccinated mice than
for spleen cells from control mice (Fig. 1D) (P  0.0001). The
proliferative response from vaccinated mice was also significantly
higher toward the heterologous parasite (P 0.0001) (Fig. 1E).
Follicular helper cells are a distinct subset of CD4 T cells that
are important in the stimulation of B cells in germinal centers and
in the induction of long-lived antibody responses (34). Consistent
with the immunoglobulin response of vaccinated mice, we ob-
served a higher percentage of CD4 T follicular helper (Tfh) cells
(Bcl6 CXCR5) in the spleens of vaccinated mice (1.48% 
0.27%) than in spleens of control mice (0.24%  0.07%; P 
0.0006) (Fig. 1F). These data thus demonstrate the induction of
both cellular and humoral immune responses after vaccination.
At 4 weeks after vaccination, mice were challenged with 105 P.
yoelii 17X pRBCs or P. yoelii YM pRBCs. Mice were strongly pro-
tected against challenge with both strains. After P. yoelii 17X chal-
lenge, peak parasitemia for control mice (33.71%  3.12%) was
reached on day 18 (in the surviving mice) (Fig. 2A). The peak
parasitemia for vaccinated mice (4.11% 0.40%) was reached on
day 4 and was significantly lower than for control mice (P 
0.0001). The peak parasitemia of control and vaccinated mice
challenged with heterologous parasites was reached on day 6 post-
challenge. However, vaccinated mice challenged with P. yoelii YM
had a significantly lower peak parasitemia (7.18% 2.22%) com-
pared to mice in the control group (56.26% 2.67%; P 0.0001)
(Fig. 2B). Reduced disease severity was observed in vaccinated
mice compared to control mice after challenge with homologous
and heterologous parasites, as measured by hemoglobin values,
clinical scores, and survival (Fig. 2C to H).
To investigate the role of B cells in protection, the responses of
immunocompromised MT mice were studied. B cell develop-
ment is blocked in the bone marrow of these mice, resulting in a
complete deficiency of mature B cells and a lack of antibodies (35).
MT mice were vaccinated with chemically attenuated P. yoelii
17X pRBCs. A control group of MT mice received chemically
treated nRBCs at each vaccination. Vaccinated immunocompe-
tent C57BL/6 mice were also included. Sera from vaccinated im-
munocompetent C57BL/6 mice collected immediately prior to
challenge contained parasite-specific IgG, whereas sera from
vaccinated MT mice did not (data not shown). Mice were
challenged 4 weeks after the final vaccination. After challenge,
vaccinated immunocompetent mice were protected with a
mean peak parasitemia of 1.62% 0.33% and reduced disease
severity (Fig. 3A, C, E, and G). Vaccinated MT mice all suc-
cumbed to infection by day 60, similarly to unvaccinated MT
mice. Vaccinated mice lived up to 20 days longer than unvac-
cinated mice, despite a similar course of parasitemia (Fig. 3B
and H). The disease profiles were similar for vaccinated and
control MT mice (Fig. 3D and F).
To determine the role of CD4 and CD8 T cells in vaccine-
induced protection, vaccinated BALB/c mice were given intraper-
itoneal injections of rat immunoglobulin (control), anti-CD4, an-
ti-CD8, or a combination of anti-CD4 and anti-CD8 antibodies.
At the time of challenge,95% depletion of the T cell subsets was
achieved (data not shown). We observed that depletion of CD4T
cells alone, or depletion of both CD4 and CD8T cells, rendered
the mice unable to control parasitemia (Fig. 4A). These mice also
had very poor clinical scores and became anemic (Fig. 4B and C).
However, all mice depleted of both cell types survived for the
duration of the study (28 days), unlike mice depleted of just CD4
T cells (Fig. 4D). Vaccinated mice depleted of CD8 T cells alone
were able to control parasite growth as effectively as vaccinated
mice that received control rat Ig and survived for the duration of
the experiment (Fig. 4A and D). The data thus show that while
CD4 T cells control parasite density, CD8 T cells not only do
not control parasite growth but contribute to a poor outcome in
the absence of CD4 T cells.
Sustained immunological memory. To assess the duration of
protection, vaccinated BALB/c mice were challenged at 3 or 9
months after the final vaccination. Age-matched control mice that
received chemically treated nRBCs were also challenged at each
time point. Peak parasitemias among vaccinated mice over the
course of infection were significantly lower than among their con-
trol counterparts at each time point (P 0.0001) (Fig. 5A to C).
Vaccinated mice challenged at 3 and 9 months after their final
vaccination showed mean parasite densities that were comparable
to those seen with mice challenged at 1 month. Also, the disease
and survival parameters were better in the vaccinated cohorts than
in their control groups at all challenge time points (Fig. 5D to L).
Immediately prior to challenge at each time point, there was no
difference in memory CD4 or CD8T cells (CD44hi CD62L) in
the blood of vaccinated and control mice (data not shown).
Splenocytes were harvested from a cohort of vaccinated but
unchallenged mice. Cytokines produced in response to parasite
stimulation were examined. At 1 and 3 months after the final
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FIG 1 Induction of immune responses after vaccination with chemically attenuated P. yoelii 17X pRBCs. (A) Vaccine-induced activation of circulating CD4
and CD8 T cells. CD49dhi CD11ahi markers were used to identify activated CD4 T cells, and CD8lo CD11ahi markers were used to identify activated CD8 T
cells in the blood of vaccinated and control mice 7 days after each injection. Data represent the mean results from 20 BALB/c mice per group. Baseline data
represent mice from both groups prior to injection. (B and C) Induction of IgG to P. yoelii 17X (B) or P. yoelii YM (C) antigens after three doses of 106 chemically
treated P. yoelii 17X pRBCs or nRBCs. IgG was measured immediately prior to challenge using sera diluted 1 in 20, and each sample was tested in duplicate. Sera
from naive mice and P. yoelii 17X or P. yoelii YM infection-drug-cured mice were included as negative and positive controls, respectively. Results are represented
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vaccination, there was significantly greater production of IL-6,
IL-10, and IFN-	 by splenocytes from vaccinated mice than from
control mice (P 0.0008) (Fig. 6A). In addition, at 3 months after
the final vaccination, IL-2 and TNF production was also signifi-
cantly higher (P 0.0048). At 9 months, there was no significant
difference in any of the measured cytokines.
Spleen cells showed significantly higher parasite-specific pro-
liferative responses than splenocytes from their respective control
groups at 1 and 3 months after their final vaccination (P 0.0001)
(Fig. 6B and C). However, there was no significant difference in
the proliferative response from vaccinated mice compared to con-
trol mice at 9 months (P 0.2809) (Fig. 6D).
We next sought to determine whether B cell memory responses
were induced by vaccination. Sera from vaccinated BALB/c mice
were taken prior to challenge with P. yoelii 17X and on day 6
postchallenge for the 1-, 3-, and 9-month assay points. Sera from
age-matched mice that received chemically treated nRBCs were
also taken pre- and postchallenge at these time points. The stim-
ulation of memory B cells is indicated by a rapid antibody re-
sponse within 6 days of restimulation with antigen, whereas a
primary immune response would take at least 9 days to produce
parasite-specific IgG (36, 37).
Parasite-specific IgG was present in the prechallenge sera of
vaccinated mice at a dilution of 1 in 20 at each time point com-
pared to sera from control mice (data not shown). In order to
assess a rapid antibody response indicative of stimulated memory
B cells, a dilution of 1 in 1,350 was used. This was the lowest
dilution across all time points at which there was no significant
difference in the prechallenge parasite-specific IgG levels between
control and vaccinated mice (1 month, P 0.9357; 3 months, P
0.9717; 9 months, P  0.0837) (Fig. 6E to G). There was no sig-
nificant difference in parasite-specific IgG in pre- and postchal-
lenge sera from control mice at 1 month (P 0.3816), 3 months
(P  0.6954), and 9 months (P  0.9948). However, sera from
vaccinated mice had significantly elevated parasite-specific IgG on
day 6 postchallenge at the 1-, 3-, and 9-month time points com-
pared to the levels prior to challenge at these time points (P 
0.0001), indicating a memory B cell response.
These data show that vaccination induced long-lasting immu-
nological memory. An increase in parasite-specific IgG in vacci-
nated mice within 6 days after challenge demonstrates the induc-
tion of memory B cell responses that remained for at least 9
months after vaccination, whereas the ability of spleen cells to
proliferate and produce cytokines in response to homologous par-
asite was sustained for at least 3 months after vaccination. This
may indicate a more prominent role for B cells in the induction of
long-lasting vaccine-induced protection.
Stage-specific immunity. During natural infection, the blood
stage of the life cycle is preceded by the liver stage. Here, CD8 T
cells are known to play a major role in protection (38, 39). Since
activation of CD8 T cells occurred postvaccination (Fig. 1A), we
sought to determine whether vaccine-induced cross-stage protec-
tion against liver-stage parasites was induced by challenging
BALB/c mice with sporozoites via mosquito bite or intravenous
injection. After sporozoite challenge, livers from control and vac-
cinated mice were harvested and homogenized to assess parasite
burden in the liver. RT-qPCRs were conducted for the Py18S par-
asite gene and the GAPDH housekeeping gene. After sporozoite
challenge by mosquito bite, there was no significant difference in the
parasite burden in the livers of vaccinated mice compared to control
mice (P 0.3277) (Fig. 7A). However, the sporozoite dose received
by each mouse cannot be controlled due to the inherent variability of
the number of sporozoites inoculated by mosquitoes (40–44). There-
fore, protection was then assessed using intravenous administration
of either freshly dissected or cryopreserved sporozoites; in both cases,
there was no significant difference in parasite burden in the livers of
vaccinated and control mice (P  0.0686 and P  0.7429, respec-
tively) (Fig. 7B and Ci).
To assess the effect of vaccination on blood-stage infection
after sporozoite challenge, a subset of mice that were challenged
with the cryopreserved sporozoites were monitored through to
the blood stage of the parasite life cycle (Fig. 7Ci). After challenge,
peak parasitemia was reached on day 8 and day 12 for vaccinated
(0.2311% 0.1548%) and control (3.52% 0.6042%) mice, re-
spectively (Fig. 7Cii). Peak parasitemia was significantly lower in
vaccinated mice than in control mice (P 0.0001) (Fig. 7Cii). In
addition, disease severity was much lower in vaccinated mice than
in control mice, with vaccinated mice experiencing a less signifi-
cant drop in hemoglobin levels (P  0.003 versus P  0.0001)
(Fig. 7Ciii) and remaining healthy (with clinical scores of zero)
(Fig. 7Civ). Mice from both groups survived (Fig. 7Cv).
DISCUSSION
We investigated the protective efficacy of chemically attenuated P.
yoelii blood-stage parasites. Vaccine-induced immunity appeared
to be directed against blood-stage parasites (both homologous
and heterologous strains), with no apparent effect against liver-
stage parasites. Immunity was dependent on both cellular and
humoral responses and was long-lived.
Investigations into the cellular immune responses induced by
vaccination with chemically attenuated P. yoelii 17X showed acti-
vated circulating CD8 T cells but only limited activation of cir-
culating CD4 T cells. However, further investigations into the
role of CD4 and CD8 T cells in vaccine-induced protection
demonstrated the crucial role of CD4 T cells after blood-stage
parasite challenge, with the depletion of CD4 T cells resulting in
a loss of protection. The limited activation of CD4 T cells ob-
served in the blood may indicate that these cells were located else-
where, for example in the spleen. Although the role of CD4 T
cells in vaccine-induced protection was evident from previous de-
pletion studies with a P. chabaudi chemically attenuated vaccine
(20), the contribution of CD8T cells remained unclear. We show
here for vaccination with P. yoelii-attenuated parasites that CD8
T cells may contribute to pathogenesis. The data suggest that they
as the optical density (OD) at 450 nm. Each group contained 10 BALB/c mice, and error bars represent the standard errors of the mean (SEM) for each group.
(D and E) Induction of splenocyte proliferation to fresh P. yoelii 17X pRBCs (D) or P. yoelii YM pRBCs (E) after three doses of 106 chemically treated P. yoelii 17X
pRBCs or nRBCs. Proliferation was evaluated by incorporation of [3H]thymidine and measured as corrected counts per minute (CCPM). Each group contained
three BALB/c mice, and error bars represent the SEM for each group. (F) Induction of CD4 Tfh cells after vaccination. The percentage of CD4 T cells
expressing Tfh markers (Bcl6 and CXCR5) was assessed in the spleens of vaccinated and control mice 2 days after the third dose. Each group contained 10 BALB/c
mice, and error bars represent the SEM for each group. **, P 0.0028; ***, P 0.001; ****, P 0.0001. An unpaired, two-tailed t test was used to compare two
experimental groups. For experiments comparing more than two groups, a one-way ANOVA was used, followed by Tukey’s multiple-comparison tests.
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FIG 2 Vaccine-induced protection against homologous and heterologous strain challenge. After three doses of 106 chemically treated P. yoelii 17X pRBCs or
nRBCs, BALB/c mice were challenged with 105 P. yoelii 17X pRBCs (left panels) or P. yoelii YM pRBCs (right panels). After challenge, parasitemias (A and B),
hemoglobin levels (C and D), clinical scores (E and F), and survival (G and H) were assessed. The vaccinated group challenged with P. yoelii 17X contained nine
mice; all other groups contained ten mice. Error bars represent the SEM for each group., mice that succumbed to infection. Peak parasitemia was significantly
lower in vaccinated mice than in control mice when challenged with homologous or heterologous parasites (****, P  0.0001). Data were analyzed using an
unpaired, two-tailed t test.
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FIG 3 Assessing the role of B cells in vaccine-induced protection following homologous challenge. Following 3 doses of 1 106 chemically treated P. yoelii 17X
pRBCs or nRBCs, C57BL/6 mice (left panels) and MT mice (right panels) were challenged with 1 105 P. yoelii 17X pRBCs. After challenge, parasitemias (A
and B), hemoglobin levels (C and D), clinical scores (E and F), and survival (G and H) were assessed. The controlMT group contained seven mice, the control
C57BL/6 group contained eight mice, and both vaccinated groups contained ten mice. Error bars show the SEM for each group. , mice that succumbed to
infection.
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require a higher parasite burden threshold to become pathogenic,
because if parasitemia is patent, but controlled by CD4 T cells,
then the CD8 T cells do not induce a deleterious response. The
mechanism by which they mediate pathogenesis was not dis-
cerned, but a vigorous cytokine response is likely to play an im-
portant role (45). We previously demonstrated that vaccination of
mice with attenuated P. chabaudi parasites led to a significant
induction of IFN-	-secreting CD8 T cells (20), and it is known
that this cytokine is implicated in pathogenesis (46, 47). However,
to the best of our knowledge, a direct demonstration of CD8 T
cells promoting disease has not previously been described. Never-
theless, this scenario is at odds with other studies documenting a
direct role for CD8 T cells in controlling parasitemia (48, 49). In
those studies, however, protection was demonstrated after the
transfer of CD8 T cells into normal mice in which CD4 T cells
were not depleted.
Cytokine analysis showed the production of both pro- and
anti-inflammatory cytokines (IFN-	, TNF, IL-2, IL-6, and IL-10)
in vaccinated mice. Proinflammatory cytokines, such as IFN-	
and TNF, are involved in the resolution of malaria and are re-
quired for protection (50, 51). IL-10 is an anti-inflammatory and
immunoregulatory cytokine produced by CD4T cells and is nec-
essary to dampen the potentially pathogenic effects of proinflam-
matory cytokines, such as IFN-	 and TNF (52). The balance of
these pro- and anti-inflammatory cytokines in vivo may limit dis-
ease severity and aid the quick resolution of blood-stage infection
associated with vaccination. This may explain the exacerbation of
immunopathology by CD8T cells in the absence of CD4T cells
and CD4 T cell-derived IL-10 (53).
The life cycle of the parasite has added complexity to the de-
velopment of a malaria vaccine. However, shared antigenic targets
(54, 55) between different life cycle stages may allow for the in-
duction of cross-stage protection (17, 33, 56, 57), which would be
valuable in the development of a malaria vaccine. Studies have
shown that exposure to blood-stage parasites under chloroquine
cover can induce cross-stage protection against liver-stage para-
sites after sporozoite challenge (17, 56). These studies are encour-
aging for the development of a whole-parasite blood-stage vaccine
candidate capable of inducing cross-stage protection. However,
our studies showed that vaccination with chemically attenuated
blood-stageP. yoelii 17X parasites was unable to induce protection
against mosquito bite or intravenous sporozoite challenge in
FIG4 Assessing the role of CD4 and CD8T cells in vaccine-induced protection following homologous challenge. (A to D) Parasitemia (A), hemoglobin levels
(B), clinical scores (C), and survival (D) in BALB/c mice that received three doses of 106 chemically attenuated P. yoelii 17X pRBCs, followed by intraperitoneal
injections of rat Ig, anti-CD4, anti-CD8, or a combination of anti-CD4 and anti-CD8 antibodies on days3,2,1, 0, 7, 15, and 22 relative to challenge with
105 P. yoelii 17X pRBCs on day 0. A naive control group was also included. The group that received rat Ig contained nine mice; all other groups contained ten mice.
Error bars show the SEM for each group., mice that succumbed to infection.
Raja et al.
2282 iai.asm.org August 2016 Volume 84 Number 8Infection and Immunity
 o
n
 August 30, 2016 by Australian National Univ.
http://iai.asm
.org/
D
ow
nloaded from
 
FIG 5 Assessing the duration of vaccine-induced protection after homologous challenge. (A to C) Parasitemia levels in BALB/c mice that received three doses
of 106 chemically treated nRBCs (control) or P. yoelii 17X pRBCs (vaccinated) prior to challenge with 105 P. yoelii 17X pRBCs at 1 month (A), 3 months (B), or
9 months (C) after the final dose. Disease severity was evaluated in control and vaccinated mice according to hemoglobin levels (D to F), clinical scores (G to I),
and survival (J to L) after homologous challenge at 1 month (left panels), 3 months (middle panels), or 9 months (right panels) after the final dose. The groups
challenged at 1 month contained nine mice; all other groups contained ten mice. Error bars show the SEM for each group., mice that succumbed to infection.
Peak parasitemia was significantly lower in vaccinated mice than in control mice at each time point (***, P 0.0001; ****, P 0.0001). Data were analyzed using
an unpaired, two-tailed t test.
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FIG 6 Vaccine-induced immune responses at 1, 3, and 9 months after completion of the vaccination regimen with chemically attenuated parasites. (A)
Production of cytokines by splenocytes in response to homologous live pRBCs at 1, 3, and 9 months after completion of the three-dose vaccination regimen with
106 chemically treated P. yoelii 17X pRBCs (vaccinated) or nRBCs (control). Culture supernatants from splenocyte proliferation assays were collected after 54 h
and used in cytokine bead arrays to quantify the level of cytokines produced. The supernatant was pooled from triplicate wells for each mouse, and error bars
represent the SEM for each group. Each group contained eight BALB/c mice. **, P 0.0048; ***, P 0.0008; ****, P 0.0001. (B to D) The proliferation of
splenocytes from control and vaccinated BALB/c mice in response to fresh P. yoelii 17X pRBCs was assessed at 1 month (B), 3 months (C), or 9 months (D) after
the final dose. The proliferation was estimated by the incorporation of [3H]thymidine and measured as corrected counts per minute (CCPM). Splenocytes from
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terms of parasite burden in the liver, as assessed by qPCR. How-
ever, when infection was monitored through to the blood stage,
vaccinated mice showed significantly lower blood-stage parasite
burdens and disease severity than control mice.
During natural exposure to blood-stage Plasmodium infection,
parasite-specific antibodies are acquired and predominate in pro-
tected individuals (2–4). Strong and long-lasting humoral im-
mune responses, which are characterized by germinal center for-
each mouse were tested in triplicate. Each group contained eight mice, and error bars represent the SEM for each group. ns, not significant. (E to G) Assessing
parasite-specific memory B cell responses at 1 month (E), 3 months (F), and 9 months (G) after completion of the three-dose vaccination regimen. The
production of IgG against crude P. yoelii 17X antigens was measured in the pre- and postchallenge sera of control and vaccinated BALB/c mice. Sera were titrated
using 3-fold dilutions from a 1 in 50 dilution to a 1 in 109,350 dilution, with the 1 in 1,350 dilution shown as a representation of the data. Samples were tested
in duplicate for each mouse. Sera from naive mice and infection-drug-cured mice were included as negative and positive controls, respectively. The results are
expressed as the optical density (OD) at 450 nm. Each group contained ten mice, and error bars represent the SEM for each group. Data were analyzed using a
one-way ANOVA, followed by Tukey’s multiple-comparison tests.
FIG 7 Assessing vaccine-induced stage-specific protection. (A to C) Parasite burden, as assessed by RT-qPCR in the livers of BALB/c mice that received four
doses of 106 chemically treated nRBCs (control; n 4) or P. yoelii 17X pRBCs (vaccinated; n 5) prior to challenge with10 bites from P. yoelii 17X-infected
mosquitoes (A), that received four doses of 106 chemically treated nRBCs (control; n 8) or P. yoelii 17X pRBCs (vaccinated; n 10) prior to challenge with
2,000 freshly dissectedP. yoelii 17X sporozoites (B), that received three doses of 106 chemically treated nRBCs (control; n 7) or P. yoelii 17X pRBCs (vaccinated;
n 6) prior to intravenous challenge with 4,000 cryopreserved P. yoelii 17X sporozoites (Ci). Error bars represent the SEM for each group. Depending on the
variation in the level of the GAPDH housekeeping gene between samples, the parasite burden in the liver was expressed as Py18S copies or normalized and
expressed as GAPDH units. (Cii to v) Assessment of parasitemia (Cii), hemoglobin levels (Ciii), clinical scores (Civ), and survival (Cv) in BALB/c mice that
received three doses of 106 chemically treated nRBCs or P. yoelii 17X pRBCs prior to intravenous challenge with 4,000 cryopreserved P. yoelii 17X sporozoites.
Each group contained ten mice, and error bars represent the SEM for each group. The peak parasitemia was significantly lower for vaccinated mice than for
control mice (****, P 0.0001). Data were analyzed using an unpaired, two-tailed t test.
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mation and long-lived plasma and memory B cells, have been
shown to be dependent on CD4 T cells with a follicular helper
cell phenotype (58, 59). Unlike previous observations with three
doses of chemically attenuated P. chabaudi blood-stage parasites
(20), vaccination with three doses of chemically attenuated P. yoe-
lii 17X blood-stage parasites did induce parasite-specific IgG. The
difference in antibody response between the two vaccines may be
due to the P. yoelii vaccine containing all the blood stages, whereas
the P. chabaudi vaccine contained only ring-stage parasites. CD4
T cells with a Tfh cell phenotype were present in higher numbers
in the spleens of mice vaccinated with the P. yoelii vaccine than in
spleens of control mice, suggesting the induction of T cell-depen-
dent antibody responses (60). An investigation into the role of B
cells in vaccine-induced protection was conducted using B cell-
deficient mice. In the absence of B cells, vaccinated mice were
unable to control parasite burden or disease severity, with out-
comes similar to those for control mice after blood-stage infec-
tion. This study also showed the importance of vaccine-induced
cellular immune responses in protection against mortality, since
vaccinated B cell-deficient mice demonstrated prolonged survival
after infection compared to control mice. However, mice in both
groups eventually succumbed to infection.
An effective vaccine should aim to induce long-lasting protec-
tive immunity. Many malaria vaccine candidates have been un-
able to induce long-lasting protection during clinical evaluation in
endemic settings (7, 8, 61). Vaccination with chemically attenu-
ated P. yoelii 17X blood-stage parasites provided long-lasting pro-
tection against homologous blood-stage challenge that was sus-
tained for at least 9 months. Memory B cells may have a role in this
long-lasting vaccine-induced protection, since a significant eleva-
tion in parasite-specific IgG was detected during early infection in
vaccinated mice. The kinetics of antibody production after chal-
lenge is indicative of a memory B cell response (37).
The development of a malaria vaccine also needs to reflect the
multitude of Plasmodium strains and species that exist and are
capable of causing disease in humans (1, 62, 63). A vaccine that is
able to provide protection against multiple strains, and also mul-
tiple species of Plasmodium, would be advantageous. We have
previously demonstrated the induction of cross-strain and species
protection after vaccination with a chemically attenuated P. cha-
baudi vaccine (20). Here, we show that mice vaccinated with
chemically attenuated P. yoelii 17X blood-stage parasites demon-
strated robust protection against heterologous blood-stage infec-
tion with the lethal P. yoelii YM strain. Although the virulent P.
yoelii YM strain was derived from an isolate of P. yoelii 17X (64),
the courses of infection of the two strains are strikingly different.
P. yoelii YM causes an extremely aggressive blood-stage infection
in BALB/c mice, with death occurring within 10 days. Therefore,
the complete protection against death and the resolution of P.
yoelii YM infection in mice vaccinated with chemically attenuated
P. yoelii 17X vaccine is encouraging for the development of this
vaccine approach.
Rodent Plasmodium spp. are crucial in understanding aspects
of human malaria and in the development of control measures
against malaria. Our studies have demonstrated that chemically
attenuated blood-stage P. yoelii 17X parasites can be used as a
robust and effective vaccine against challenge with homologous
and heterologous blood-stage P. yoelii parasites in mice. Long-
lasting vaccine-induced protection and immunological responses
were demonstrated against homologous parasites. These data are
very encouraging for the development of an effective chemically
attenuated blood-stage Plasmodium vaccine for use in humans.
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